Access Pharmaceuticals, Reduce Glucose Levels in Pre-clinical Testing of Cobalamin Oral Insulin

Dec. 7 , 2007 - Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) announced that it has demonstrated the ability, using the company's proprietary Cobalamin(TM) technology, to significantly reduce glucose levels in an animal model of diabetes, through its oral insulin product candidate. Several formulations using Cobalamin, which is based upon the body's natural absorption of vitamin B12 in the gastrointestinal tract, were tested in an animal model of diabetes. Additional pre-clinical studies are planned... [PDF] Access Pharmaceuticals' Press Release -

Keryx , Sulodexide Phase 3 study to continue without modification

Dec. 5, 2007 - Keryx Biopharmaceuticals (Nasdaq: KERX) announced that the Independent Data Safety Monitoring Committee (DSMC) responsible for monitoring Sulonex(TM) (sulodexide oral gelcaps), the Company's lead drug candidate under development as a treatment for diabetic nephropathy , recently met to evaluate the data from the ongoing Phase 3 trial... Keryx Biopharmaceuticals' Press Release -

Targacept , TC-6499, Neuropathic Pain Candidate

December 10, 2007 - Targacept, Inc. (Nasdaq: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), announced that it has initiated a Phase I clinical trial of its product candidate TC-6499. The initiation of the trial triggers a $6.0 million milestone payment to Targacept under the terms of its alliance agreement with GlaxoSmithKline...Neuropathic pain is characterized as severe, stabbing, burning or tingling and is most often associated with diabetes mellitus... Targacept's Press Release -

Trinity Biotech, FDA Clearance of TRIstat Point-of-Care HbA1c Test

November 29th, 2007 - Trinity Biotech plc (NASDAQ: TRIB) a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced that the US Food and Drug Administration has given clearance to market the rapid, point-of-care TRIstat™ HbA1c system... [PDF] Trinity Biotech's Press Release -

Phase IIb Trial of EpiCept NP-1 in Diabetic Peripheral Neuropathy

Dec 03, 2007 - EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced that it has completed patient enrollment in the Phase IIb "Neuracept" trial for EpiCept(TM) NP-1 cream. EpiCept NP-1 is a patented topical cream formulation of two FDA- approved drugs, 4% amitriptyline and 2% ketamine, and is intended to provide long-term relief from the pain of peripheral neuropathies... EpiCept 's Press Release -